{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:46:05Z","timestamp":1773812765801,"version":"3.50.1"},"reference-count":33,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Health Laboratory Service Research Trust","award":["GRANT00494739"],"award-info":[{"award-number":["GRANT00494739"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Multidrug-resistant (MDR) Gram-negative bacteria are responsible for the majority of healthcare-associated infections and pose a serious threat as they complicate and prolong clinical care. A novel cephalosporin-\u03b2-lactamase-inhibitor combination, ceftolozane-tazobactam (C\/T) was introduced in 2014, which improved the treatment of MDR pathogens. This study aimed to evaluate the activity of C\/T against Escherichia coli (n = 100), Klebsiella pneumoniae (n = 100), and Pseudomonas aeruginosa (n = 100) blood culture isolates in South Africa (SA). Isolates were sequentially selected (2010 to 2020) from the Group for Enteric, Respiratory, and Meningeal Diseases Surveillance (GERMS) programme in SA. Organism identification was performed using the matrix-assisted laser desorption\/ionisation-time of flight mass spectrometry (MALDI-TOF MS) instrument (Microflex, Bruker Daltonics, Bremen, Germany), and antibiotic susceptibility was performed using the Sensititre instrument (Trek Diagnostic Systems, East Grinstead, UK). C\/T resistance was reported in 16 E. coli, 28 K. pneumoniae and 13 P. aeruginosa isolates. Fifty percent of the C\/T resistant isolates were subjected to whole-genome sequencing (WGS). According to the whole genome multilocus sequence typing (MLST) analysis, the E. coli isolates (n = 8) belonged to sequence type (ST)10, ST131, ST405, and ST410, the K. pneumoniae isolates (n = 14) belonged to ST1, ST37, ST73, ST101, ST231, ST307, ST336 and ST6065 (novel ST), and the P. aeruginosa isolates (n = 7) belonged to ST111, ST233, ST273, and ST815. The WGS data also showed that all the E. coli isolates harboured aminoglycoside (aph (3\u2032\u2032)-Ib, aph (6)-Id), macrolide (mdfA, mphA), and sulphonamide (sul2) antibiotic resistance genes, all the K. pneumoniae isolates harboured \u03b2-lactam (blaCTX-M-15), and sulphonamide (sul2) antibiotic resistance genes, and all the P. aeruginosa isolates harboured aminoglycoside (aph (3\u2032)-IIb), \u03b2-lactam (PAO), fosfomycin (fosA), phenicol (catB7), quinolone (crpP), and disinfectant (qacE) antibiotic resistance genes. It is evident that E. coli, K. pneumoniae and P. aeruginosa can adapt pre-existing resistance mechanisms to resist newer \u03b2-lactam molecules and inhibitors, since these isolates were not exposed to ceftolozane-tazobactam previously.<\/jats:p>","DOI":"10.3390\/antibiotics12030453","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T03:23:36Z","timestamp":1677468216000},"page":"453","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["In Vitro Activity of Ceftolozane-Tazobactam against Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa Obtained from Blood Cultures from Sentinel Public Hospitals in South Africa"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5580-4629","authenticated-orcid":false,"given":"Olga","family":"Perovic","sequence":"first","affiliation":[{"name":"Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses, National Institute for Communicable Diseases a Division of the National Health Laboratory Service, Johannesburg 2192, South Africa"},{"name":"Department of Clinical Microbiology and Infectious Diseases, School of Pathology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg 2193, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashika","family":"Singh-Moodley","sequence":"additional","affiliation":[{"name":"Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses, National Institute for Communicable Diseases a Division of the National Health Laboratory Service, Johannesburg 2192, South Africa"},{"name":"Department of Clinical Microbiology and Infectious Diseases, School of Pathology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg 2193, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6399-6229","authenticated-orcid":false,"given":"Michelle","family":"Lowe","sequence":"additional","affiliation":[{"name":"Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses, National Institute for Communicable Diseases a Division of the National Health Laboratory Service, Johannesburg 2192, South Africa"},{"name":"Department of Clinical Microbiology and Infectious Diseases, School of Pathology, Faculty of Health Sciences, University of Witwatersrand, Johannesburg 2193, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.clinthera.2015.05.501","article-title":"Susceptibility Profile of Ceftolozane\/Tazobactam and Other Parenteral Antimicrobials against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from US Hospitals","volume":"37","author":"Sutherland","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009\u20132010","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect. Control. Hosp. Epidemiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","article-title":"New agents for the treatment of infections with Gram-negative bacteria: Restoring the miracle or false dawn?","volume":"23","author":"Wright","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s10096-021-04308-0","article-title":"The ERACE-PA Global Surveillance Program: Ceftolozane\/tazobactam and Ceftazidime\/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa","volume":"40","author":"Gill","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e0198521","DOI":"10.1128\/aac.01985-21","article-title":"Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other \u03b2-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program","volume":"66","author":"Lin","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","first-page":"825","article-title":"Ceftolozane\/Tazobactam: A new option in the treatment of complicated gram-negative infections","volume":"39","author":"Sorbera","year":"2014","journal-title":"P T A Peer-Rev. J. Formul. Manag."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jiph.2022.02.009","article-title":"In-vitro activity of ceftolozane\/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals","volume":"15","author":"Bahabri","year":"2022","journal-title":"J. Infect. Public Health"},{"key":"ref_8","first-page":"10","article-title":"Best practices: Appropriate use of the new \u03b2-lactam\/\u03b2-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa","volume":"37","author":"Brink","year":"2022","journal-title":"S. Afr. J. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"729","DOI":"10.7196\/SAMJ.2021.v111i8.15762","article-title":"Using ceftazidime-avibactam for persistent carbapenem-resistant Serratia marcescens infection highlights antimicrobial stewardship challenges with new beta-lactam-inhibitor combination antibiotics","volume":"111","author":"Tootla","year":"2021","journal-title":"S. Afr. Med. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s10096-020-03845-4","article-title":"Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018","volume":"39","author":"Perovic","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ijantimicag.2017.06.024","article-title":"In-vitro activity of ceftolozane\/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany","volume":"51","author":"Seifert","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12941-022-00528-0","article-title":"Ceftolozane\/tazobactam for the treatment of bacteremia: A systematic literature review (SLR)","volume":"21","author":"Khankhel","year":"2022","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_13","first-page":"1262","article-title":"Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane\/tazobactam","volume":"72","author":"Nodar","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011\u20132012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jgar.2018.01.010","article-title":"Clinical experience with ceftolozane\/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa","volume":"13","author":"Xipell","year":"2018","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"dlaa084","DOI":"10.1093\/jacamr\/dlaa084","article-title":"WGS characterization of MDR Enterobacterales with different ceftolozane\/tazobactam susceptibility profiles during the SUPERIOR surveillance study in Spain","volume":"2","author":"Bou","year":"2020","journal-title":"JAC-Antimicrobial Resist."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1093\/jac\/dkac184","article-title":"Ceftolozane\/tazobactam for hospital-acquired\/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: A subgroup analysis of the ASPECT-NP clinical trial","volume":"77","author":"Paterson","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e0206721","DOI":"10.1128\/aac.02067-21","article-title":"Selection of AmpC \u03b2-Lactamase Variants and Metallo-\u03b2-Lactamases Leading to Ceftolozane\/Tazobactam and Ceftazidime\/Avibactam Resistance during Treatment of MDR\/XDR Pseudomonas aeruginosa Infections","volume":"66","author":"Gato","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jac\/dkac385","article-title":"Phenotypic and genotypic profile of ceftolozane\/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa","volume":"78","author":"Gill","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_21","unstructured":"CLSI (2021). Performance Standards for Antimicrobial Susceptibility Testing, Clinical and Laboratory Standards Institute. [31st ed.]. CLSI Supplement M100."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14806\/ej.17.1.200","article-title":"Cutadapt removes adapter sequences from high-throughput sequencing reads","volume":"17","author":"Martin","year":"2011","journal-title":"EMBnet. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13059-018-1540-z","article-title":"SKESA: Strategic k-mer extension for scrupulous assemblies","volume":"19","author":"Souvorov","year":"2018","journal-title":"Genome Biol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Souvorov, A., and Agarwala, R. (2021). SAUTE: Sequence assembly using target enrichment. BMC Bioinform., 22.","DOI":"10.1186\/s12859-021-04174-9"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/bioinformatics\/btt086","article-title":"QUAST: Quality assessment tool for genome assemblies","volume":"29","author":"Gurevich","year":"2013","journal-title":"Bioinformatics"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Jolley, K.A., and Maiden, M.C. (2010). BIGSdb: Scalable analysis of bacterial genome variation at the population level. BMC Bioinform., 11.","DOI":"10.1186\/1471-2105-11-595"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1093\/jac\/dkaa345","article-title":"ResFinder 4.0 for predictions of phenotypes from genotypes","volume":"75","author":"Bortolaia","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_29","first-page":"D517","article-title":"CARD 2020: Antibiotic resistome surveillance with the comprehensive antibiotic resistance database","volume":"48","author":"Alcock","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"D566","DOI":"10.1093\/nar\/gkw1004","article-title":"CARD 2017: Expansion and model-centric curation of the comprehensive antibiotic resistance database","volume":"45","author":"Jia","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"D687","DOI":"10.1093\/nar\/gky1080","article-title":"VFDB 2019: A comparative pathogenomic platform with an interactive web interface","volume":"47","author":"Liu","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"D325","DOI":"10.1093\/nar\/gki008","article-title":"VFDB: A reference database for bacterial virulence factors","volume":"33","author":"Chen","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"ref_33","first-page":"000748","article-title":"ResFinder\u2014An open online resource for identification of antimicrobial resistance genes in next-generation sequencing data and prediction of phenotypes from genotypes","volume":"8","author":"Florensa","year":"2022","journal-title":"Microb. Genom."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/3\/453\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:41:35Z","timestamp":1760121695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/3\/453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["antibiotics12030453"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12030453","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]}}}